FDA Updates for Week of March 11: First CAR-T for CLL/SLL and First NASH Treatment
March 16th 2024The FDA this week approved a few firsts: the first treatment for NASH and the first CAR-T cell therapy for CLL/SLL. Other approvals include Tevimbra for esophageal cancer; Livmarli for second liver disease indication; and Praluent for children with genetic form of high cholesterol. The FDA also issued a CRL for monthly MS drug. Additionally, Celltrion submitted an application for an interchangeable Xolair biosimilar.
Read More
Healthcare Ready, a nonprofit organization committed to protecting the U.S. healthcare system against disasters and pandemics, recently concluded an initiative aimed to understand the consequences of the COVID-19 pandemic and other disaster-related threats on the healthcare workforce.
Read More
The Rise in ‘Menopause’ and ‘Mommy Makeovers’: Navigating Aging and Hormonal Shifts with Aesthetics
March 13th 2024As women age, hormonal shifts during menopause often bring visible changes in their physical appearance. Cynthia Elliott, M.D., owner and primary practitioner at Skinspirations, shed light on the concept of "menopause makeovers" and how medical aesthetic procedures can address these changes toward women.
Read More
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
March 12th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More
The clinical associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, spoke in a session over the weekend at the American Academy Dermatology meeting about conditions that may mimic atopic dermatitis.
Read More
Oral Drug for Hidradenitis Suppurativa Shows Promise in Small Study | AAD 2024
March 9th 2024A phase 2 study demonstrated positive results for remibrutinib, a BTK inhibitor, as a treatment for patients with the rare skin condition, hidradenitis suppurativa, finds a study presented at the American Academy of Dermatology Association.
Read More
Robert Sidbury Talks Practice Management and Value-Based Care | AAD 2024
March 9th 2024In a discussion with Managed Healthcare Executive, Robert Sidbury, M.D., M.P.H, FAAD, professor of pediatrics at the Seattle Children's Hospital talks about what it takes to run a dermatology practice and how to implement value-based care initiatives.
Read More
FDA Updates for Week of March 4, 2024: Wegovy Gets New Indication
March 9th 2024The FDA has approved Wegovy for reducing cardiovascular risks in people who are obese or overweights. The agency approved new biosimilars that reference Actema, Prolia and Xgeva. Additionally, the FDA plans to hold advisory committee meeting for donanemab in Alzheimer’s disease.
Read More
What Do TikTok Videos Have To Say About Isotretinoin? | AAD 2024
March 9th 2024A content analysis of 75 TikTok videos showed that most have positive information about the oral acne medication, which was previously sold under the brand name Accutane. But larger majority (77%) of the videos have negative information about isotretinoin, and a large percentage of those videos give the positive effects only a passing mention, if any at all.
Read More